Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/17/2025

Anticoagulation in Chronic Kidney Disease

Introduction to Anticoagulation

  • Anticoagulation therapy is crucial in patients with renal infarction, with the European Society of Cardiology and American College of Cardiology providing guidelines for its use 1, 2
  • The American College of Cardiology recommends apixaban as the preferred anticoagulant for patients with atrial fibrillation and kidney failure due to its superior safety profile and lower bleeding risk compared to warfarin 2

Choice of Anticoagulant

  • Apixaban is safe and is the preferred oral anticoagulant for patients with CKD stage 4, with appropriate dose adjustment to 2.5 mg twice daily, according to the European Heart Rhythm Association and Kidney International guidelines 3, 4
  • The European Heart Rhythm Association practical guide approves apixaban for use in severe CKD (Stage 4) with reduced dosing 3
  • Dabigatran is contraindicated in CKD stage 4 due to its high renal clearance of 80%, and alternative anticoagulants like apixaban should be considered instead 3
  • Rivaroxaban and edoxaban should be used with caution in CKD stage 4 due to their higher renal clearance compared to apixaban, highlighting the need for careful dose adjustment and monitoring 3

Dosing and Administration

  • The standard dose of apixaban for patients with CKD stage 4 (CrCl 15-29 mL/min) is 2.5 mg twice daily, as recommended by the Kidney International guidelines 4
  • The standard dosing of apixaban is 5 mg twice daily, unless dose reduction criteria are met, in which case the dose is reduced to 2.5 mg twice daily if 2 of 3 criteria are present (age >80 years, weight <60 kg, or serum creatinine >133 μmol/L) 5
  • Apixaban 2.5 mg twice daily is the preferred option for patients with kidney failure, with rivaroxaban 15 mg daily and edoxaban 30 mg daily as alternative options, although with a higher bleeding risk 5
  • The following table summarizes the renal clearance and use of DOAKs in patients with GFR <30 mL/min:
DOAC Renal Clearance Use in GFR <30 mL/min
Apixaban 27% Approved (2.5 mg BID)
Rivaroxaban 35% Contraindicated
Edoxaban 50% Contraindicated
Dabigatran 80% Contraindicated

6

  • For low bleeding risk procedures, apixaban should be stopped 48 hours before, and for high bleeding risk procedures, it should be stopped 96 hours before, as recommended by the Kidney International guidelines 4
  • No bridging with LMWH/UFH is required when interrupting apixaban for procedures, according to the Kidney International guidelines 4
  • CrCl 30-50 mL/min: Stop apixaban/edoxaban/rivaroxaban 48h (low risk) to 96h (high risk) before procedure, according to the Kidney International guideline 4

Safety Considerations and Monitoring

  • Renal function should be assessed before initiating anticoagulation and at least annually thereafter, with more frequent monitoring (every 3-6 months) in patients with fluctuating renal function 7
  • Concomitant antiplatelet therapy should be used very judiciously as it substantially increases bleeding risk 5
  • Regular assessment of renal function (every 3-6 months) is recommended for all patients on anticoagulation, with more frequent monitoring during acute illness, and INR monitoring at least weekly during warfarin initiation and monthly when stable 8

Guidelines and Recommendations

  • The 2024 KDIGO guidelines recommend NOACs, particularly apixaban, over vitamin K antagonists for thromboprophylaxis in CKD G1-G4, due to their improved safety profile 4
  • The American College of Cardiology, European Heart Rhythm Association, and Kidney International guideline recommend NOACs, such as apixaban, in preference to vitamin K antagonists for thromboprophylaxis in atrial fibrillation in CKD G1-G4, based on high-quality evidence 4, 2, 3
  • The American Heart Association, American College of Cardiology, and Heart Rhythm Society provide a Class IIb recommendation for apixaban in patients with a CHA₂DS₂-VASc score ≥2 in men or ≥3 in women with end-stage CKD or on dialysis 7
  • For patients with CrCl >30 mL/min, the American College of Cardiology prefers DOACs over warfarin, with apixaban having the strongest evidence for safety 2
  • For patients with CrCl 15-30 mL/min, apixaban with appropriate dose reduction (2.5 mg BID) is considered, while warfarin is an alternative but requires close monitoring 2
  • For patients with CrCl <15 mL/min or on dialysis, warfarin remains the standard of care, although evidence for benefit is limited, and careful consideration of risks vs. benefits is necessary 2, 9

REFERENCES